Radiant Research is enrolling subjects and establishing operational plans for upcoming H1N1 vaccine trials.
Michael Kritschgau, Vice President of Radiant, said: “We have over a million subjects in our database and they are both familiar with the research process and very interested in this type of trial.”
“We are currently making contact with these potential subjects so we can be ready to enroll once the manufacturers are ready to move to the clinical trials stage. We anticipate that companies producing the vaccine will soon be reaching out to various research facilities; we will be ready when we get that call,” he added.
WHO has declared the H1N1 influenza outbreak a pandemic and CDC has shipped virus samples to several manufacturers, with the hope of having vaccine available to the general public by the fall.